IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 71,077 shares of the medical research company’s stock after purchasing an additional 888 shares during the period. Asset Management One Co. Ltd.’s holdings in IQVIA were worth $16,843,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Park Place Capital Corp acquired a new position in shares of IQVIA in the third quarter worth about $28,000. Versant Capital Management Inc grew its position in IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the 2nd quarter valued at $27,000. Itau Unibanco Holding S.A. acquired a new stake in shares of IQVIA in the second quarter worth $29,000. Finally, International Assets Investment Management LLC acquired a new position in IQVIA during the second quarter valued at $32,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research analyst reports. Barclays reduced their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft decreased their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. BTIG Research dropped their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus price target of $259.13.

IQVIA Trading Up 1.3 %

IQVIA stock opened at $212.96 on Wednesday. The business’s 50-day simple moving average is $232.84 and its 200-day simple moving average is $229.54. IQVIA Holdings Inc. has a 52 week low of $190.20 and a 52 week high of $261.73. The firm has a market capitalization of $38.65 billion, a PE ratio of 27.95, a PEG ratio of 2.07 and a beta of 1.51. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.